- Business
- Polaris Group (TWSE: 6550) is a Cayman Islands-incorporated multinational biotechnology company that engages in the research, development, manufacture, and sale of novel anti-cancer therapies, peptide drugs, active pharmaceutical ingredients (API), generics, and provides contract development and manufacturing organization (CDMO) services, drug testing, and other biotechnology services. The company offers its lead drug candidate Pegargiminase (ADI-PEG 20), a biologic targeting arginine deprivation for late-stage clinical development in cancers including hepatocellular carcinoma, malignant pleural mesothelioma (MPM), pancreatic cancer, non-small cell lung cancer, melanoma, and acute myeloid leukemia; through subsidiaries such as Genovior Biotech Corporation, it manufactures sterile injectables, fully synthetic peptides, and specialty dosage forms, while DesigneRx Pharmaceuticals, Inc., Nanotein Technologies, Inc., DesigneRx Pharmaceuticals (Chengdu), Inc., and Polaris Pharmaceuticals, Inc. support structure-based drug design, cGMP production in Northern California and China, and clinical studies at top-tier cancer centers worldwide. Polaris Group operates across North America, Asia, and pursues global markets including Latin America and the Gulf Cooperation Council region, with headquarters effectively in Taiwan and key facilities in the United States and China; founded on February 9, 2006, it targets pharmaceutical companies, healthcare providers, and patients with hard-to-treat cancers. Recent developments include Genovior Biotech's expansion of sterile injection capacity for global supply of synthetic peptides and injectables; a non-exclusive commercialization agreement with MNR Therapeutics for Fulvestrant in the GCC region in November 2025; Polaris Pharmaceuticals Inc.'s exclusive in-licensing partnership with Bioprofarma Bagó in July 2025 to introduce ADI-PEG 20 in Argentina and other Latin American markets; and the U.S. FDA's entry into substantive review of the Biologic License Application for ADI-PEG 20, indicated with platinum and pemetrexed for non-epithelioid MPM, following full submission in June 2025.